Soult J A, Muñoz M, Lopez J D, Romero A, Santos J, Tovaruela A
Department of Pediatrics, Virgen Rocio Children's Hospital, Seville University School of Medicine, Spain.
Pediatr Cardiol. 1995 Jan-Feb;16(1):16-9. doi: 10.1007/BF02310328.
The use of intravenous amiodarone was assessed during 23 episodes of paroxysmal supraventricular tachycardia in 15 children aged 9 days to 11 years. Five of the fifteen patients had congenital structural heart disease, and three had Wolf-Parkinson-White syndrome. Tachyarrhythmias were returned to sinus rhythm during 20 of the 23 episodes (87%). No major adverse effects occurred. Recurrence of tachycardia was not observed during short-term follow-up. In conclusion, intravenous amiodarone is an effective, safe antiarrhythmic drug for short-term treatment of supraventricular tachycardia in children.
